ReviewMethods in molecular medicine2005
Gene transfer in endothelial dysfunction and hypertension.
Review in Methods in molecular medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02964585 (Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Antioxidant-upregulated mesenchymal stem cells reduce inflammation and improve fatty liver disease in diet-induced obesity.Stem cell research & therapy · 2019Article
- Use of p53-Silenced Endothelial Progenitor Cells to Treat Ischemia in Diabetic Peripheral Vascular Disease.Journal of the American Heart Association · 2017Article
- Redox Control of Vascular Biology.Oxidative medicine and cellular longevityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene transfer represents a method for treatment of several cardiovascular disorders, including endothelial dysfunction and hypertension. For effective and safe gene therapy in vascular disease, a suitable therapeutic gene needs to be identified and delivered to the vasculature by appropriate delivery devices. In this chapter, we review the different vectors used, both viral and nonviral, suitable genes identified, and associated delivery devices. Several genes have been identified with a view to improve endothelial dysfunction, and we have elaborated the advantages and disadvantages of these approaches. Strategies to treat hypertension, both systemic and pulmonary, have also been described. The optimal vector has not yet been discovered although a wide variety of choices is available, each with properties that may render it suitable for specific applications. The individual characteristics of these vectors are described in relation to the proposed therapeutic paradigm. Although there are several unanswered questions in this arena, the future application of gene transfer technology to diseases of the vasculature holds significant promise.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.